BMS, Apothecon Pay $515M To Settle Pricing Claims
Bristol-Myers Squibb Co. and its former generic subsidiary Apothecon BV have agreed to pay over $515 million to put to rest allegations of illegal drug pricing schemes, the U.S. Attorney for...To view the full article, register now.
Already a subscriber? Click here to view full article